The investment will support MABT’s continued clinical development, research initiatives, and regulatory milestones. The first funding tranche is expected in Q3 2025, marking a new chapter of growth for the company. MABT plans to initiate Phase 3 clinical trial for its lead viral encephalitis drug in 2026 and advance new clinical programs utilizing an AI computational chemistry/structure & fragment-based discovery and development platform. MABT also plans to seek potential public listing via IPO or reverse merger within 18 months.
Legend Innovation Life Science Fund announced an investment commitment of up to $50 million in Mid-Atlantic BioTherapeutics (“MABT”), a clinical-stage biotechnology company headquartered in Pennsylvania and focused on advancing novel therapies for anti-aging, including neurological diseases and cancer.
“Our dedication to transformative healthcare innovation is reflected in this partnership with Mid-Atlantic BioTherapeutics,” said Dr. Syngbum (Ben) Kim, Chairman and Founder of Legend. “MABT’s scientific vision and strong leadership make them an ideal investment for our fund as we work to rapidly translate pioneering research into real-world therapies for patients in need.”
Read More on Fintech : Global Fintech Interview with Kevin Wall, Chief Financial Officer at Stax
Legend is a leading biotech investment fund that accelerates AI-driven drug innovation for anti-aging/regeneration and delivers high-value returns to investors. Legend Fund invests in companies leveraging the power of AI-driven drug design to revolutionize drug discovery. Legend focuses its strategic investments in Pre-IPO biotech companies ready for an exit via public listing. Legend also looks to unlock value in unique top-quality overseas companies by investing and facilitating successful U.S. public listings.
Dr. David Horn, CEO and Founder of Mid-Atlantic BioTherapeutics, commented, “We are honored by Legend’s confidence in our technology and mission. This strategic investment will enable us to accelerate our programs targeting various aspects of anti-aging. With Legend’s support, we are positioned to accelerate our programs that aim to extend the length and quality of people’s lives.”
The investment will support MABT’s continued clinical development, research initiatives, and regulatory milestones. The first funding tranche is expected in Q3 2025, marking a new chapter of growth for the company. MABT plans to initiate Phase 3 clinical trial for its lead viral encephalitis drug in 2026 and advance new clinical programs utilizing an AI computational chemistry/structure & fragment-based discovery and development platform. MABT also plans to seek potential public listing via IPO or reverse merger within 18 months.
Both organizations look forward to a partnership that can deliver impactful advances for patients and set new benchmarks for innovation within the biotechnology industry.
Catch more Fintech Insights : The Impact of Open Banking on Cross-Carrier Data Sharing in Insurance
[To share your insights with us, please write to psen@itechseries.com ]
